



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Ana Jiménez-Ubieto

✉ anitiju@hotmail.com

Santiago Barrio

✉ santiago_barrio@altumsequencing.com

[†]These authors have contributed equally to this work

RECEIVED 20 June 2023

ACCEPTED 08 August 2023

PUBLISHED 16 August 2023

CITATION

Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena M-T, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J and Barrio S (2023) Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients. *Front. Immunol.* 14:1243241. doi: 10.3389/fimmu.2023.1243241

COPYRIGHT

© 2023 Jiménez-Ubieto, Martín-Muñoz, Poza, Dorado, García-Ortiz, Revilla, Sarandeses, Ruiz-Heredia, Baumann, Rodríguez, Calbacho, Sánchez, Pina, García-Sancho, Figaredo, Rufián, Rodríguez, Carneros, Martínez-Laperche, Bastos-Oreiro, Wang, Cedena, Rapado, de Toledo, Gallardo, Valeri, Ayala, Martínez-López and Barrio. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients

Ana Jiménez-Ubieto^{1*†}, Alejandro Martín-Muñoz^{1,2†}, María Poza¹, Sara Dorado^{2,3}, Almudena García-Ortiz¹, Enrique Revilla⁴, Pilar Sarandeses⁵, Yanira Ruiz-Heredia^{1,2}, Tycho Baumann¹, Antonia Rodríguez¹, María Calbacho¹, Pilar Martínez Sánchez¹, José María Sánchez Pina¹, Alejandro Martín García-Sancho⁶, Gloria Figaredo¹, Laura Rufián^{1,2}, Margarita Rodríguez^{1,2}, Laura Carneros¹, Carolina Martínez-Laperche⁷, Mariana Bastos-Oreiro⁷, Chongwu Wang⁸, María-Teresa Cedena¹, Inmaculada Rapado¹, Paula de Toledo³, Miguel Gallardo¹, Antonio Valeri¹, Rosa Ayala¹, Joaquín Martínez-López¹ and Santiago Barrio^{1,2*}

¹Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain, ²Altum sequencing Co., Madrid, Spain, ³Computational Science Department, Carlos III University, Madrid, Spain, ⁴Departamento de Anatomía Patológica, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Departamento de Medicina Nuclear, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Department of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain, ⁷Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁸Hosea Precision Medical Technology Co., Ltd., Weihai, Shangdong, China

KEYWORDS

follicular lymphoma, ctDNA (circulating tumor DNA), NGS (Next-Generation Sequencing), minimal residual disease, monitoring, PET/CT 18F-FDG, CAR T-cell therapy

A Corrigendum on

Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.

By Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena M-T, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J and Barrio S (2023). *Front. Immunol.* 14:1188818. doi: 10.3389/fimmu.2023.1188818

In the published article, there was an error in the author list, and author Miguel Gallardo was erroneously excluded. The corrected author list appears below:

Ana Jiménez-Ubieto^{1*†}, Alejandro Martí'n-Muñoz^{1,2†}, María Poza¹, Sara Dorado^{2,3}, Almudena García-Ortiz¹, Enrique Revilla⁴, Pilar Sarandeses⁵, Yanira Ruiz-Heredia^{1,2}, Tycho Baumann¹, Antonia Rodríguez¹, María Calbacho¹, Pilar Martínez Sánchez¹, José María Sánchez Pina¹, Alejandro Martín García-Sancho⁶, Gloria Figaredo¹, Laura Rufián^{1,2}, Margarita Rodríguez^{1,2}, Laura Carneros¹, Carolina Martínez-Laperche⁷, Mariana Bastos-Oreiro⁷, Chongwu Wang⁸, María-Teresa Cedena¹, Inmaculada Rapado¹, Paula de Toledo³, Miguel Gallardo¹, Antonio Valeri¹, Rosa Ayala¹, Joaquín Martínez-López¹ and Santiago Barrio^{1,2}.

The updated author contribution section appears below:

AJ-U, AM-M, MP, and SB designed the research. LR, AG-O, ER, PS and MR performed the experiments. AM-M, YR-H, SD, CW, and SB defined the bioinformatic pipeline and performed sequencing data analysis. AJ-U, MP, ER, TB, AR, MC, GF, M-TC,

RA and JM-L provided patient samples and clinical data. Author MG contributed to the conception, design and manuscript revisions. All authors analyzed and interpreted the data. AJ-U, AM-M, MP, and SB wrote the manuscript which was approved by all authors.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.